New Horizons of Model Informed Drug Development in Rare Diseases Drug Development Blog Post
Model-informed drug development is revolutionizing the way we approach rare diseases, where traditional large-scale clinical trials may be impractical or even unethical. By integrating nonclinical and clinical data, these quantitative...
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio Blog Post
Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance Radnor, PA – 2024 年 7 月 9 日 - Certara, Inc. （纳斯达克股票代码：CERT）今日宣布任命李改玲博...
Transforming Non-clinical Drug Development with SEND Explorer Blog Post
Since 1999, Genmab has been developing therapeutic antibodies and antibody-drug conjugates (ADCs) for treating cancer. Their non-clinical safety group analyzes complex toxicology data that they receive from the CROs that...A literature review of drug transport mechanisms during lactation Blog Post
The literature review titled “A literature review of drug transport mechanisms during lactation,” authored by Christine Gong, Lynn N. Bertagnolli, David W. Boulton, and Paola Coppola, consolidates current knowledge on…
3 Things You Should Know About ADaM Standards Blog Post
Learn the key aspects of ADaM standards, including the difference between SDTM and ADaM and the importance of traceability.
Technologies for the analysis and utilization of vast amounts of data in drug discovery research [Japan Webinar] Blog Post
本网络研讨会以日语进行。Certara introduced D360, a drug discovery research platform, focusing on its functional features such as no-code data collection, assay result display, chemical…
University of Florida Wins 2023/24 Certara-Simcyp™ Grant and Partnership Scheme Blog Post
RADNOR, PA — 2024 年 7 月 3 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation, is pleased to announce that the University of Florida has been awarded the prestigious…
Phoenix UGM Europe 2024 Blog Post
Join the worldwide Phoenix user community and the Certara Phoenix team to learn how our solutions are accelerating drug development. The meeting will include presentations from Phoenix users and updates…
Categorizing & Managing Risks in Aggregate Safety Reports Blog Post
Categorizing Risks From a sponsor’s first authorization to conduct a clinical drug trial in any country worldwide, they must prepare and submit development safety update reports (DSURs) annually. The purpose…
